{"filing":{"accession_number":"0001764013-26-000062","cik":"0001764013","ticker":"IMVT","company_name":"Immunovant, Inc.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"imvt-20260520.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/imvt-20260520.htm"},"events":[{"id":9947,"run_id":8722,"accession_number":"0001764013-26-000062","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing discloses a press release announcing financial results for the fourth quarter and fiscal year ended March 31, 2026, which is a standard earnings release. The Item 2.02 classification and reference to Exhibit 99.1 containing the press release are characteristic of earnings disclosures. This is material to investors as it provides periodic financial performance information.","company_name":"Immunovant, Inc.","ticker":"IMVT","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":781,"accession_number":"0001764013-26-000062","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses a press release announcing financial results for the fourth quarter and fiscal year ended March 31, 2026, which is a standard earnings release. The Item 2.02 classification and reference to Exhibit 99.1 containing the press release are characteristic of earnings disclosures. This is material to investors as it provides periodic financial performance information.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:57:18.510872+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":781,"accession_number":"0001764013-26-000062","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses a press release announcing financial results for the fourth quarter and fiscal year ended March 31, 2026, which is a standard earnings release. The Item 2.02 classification and reference to Exhibit 99.1 containing the press release are characteristic of earnings disclosures. This is material to investors as it provides periodic financial performance information.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:57:18.510872+00:00","company_name":"Immunovant, Inc.","ticker":"IMVT","filing_date":"2026-05-20"}]}